Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
|
|
Pasithea Therapeutics Corp.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/13/2023 |
8-K
| Quarterly results |
| 08/24/2023 |
SC TO-I/A
| Form SC TO-I/A - Tender offer statement by Issuer: [Amend] |
| 08/21/2023 |
SC TO-I/A
| Form SC TO-I/A - Tender offer statement by Issuer: [Amend] |
| 08/14/2023 |
SC TO-I/A
| Form SC TO-I/A - Tender offer statement by Issuer: [Amend] |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
SC TO-I
| Form SC TO-I - Tender offer statement by Issuer: |
| 07/20/2023 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 07/20/2023 |
8-K
| Quarterly results |
| 07/20/2023 |
8-K
| Quarterly results |
| 07/03/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 06/06/2023 |
4/A
| STEINMAN LAWRENCE (Director) has filed a Form 4 on Pasithea Therapeutics Corp. |
| 06/06/2023 |
4
| STEINMAN LAWRENCE (Director) has filed a Form 4 on Pasithea Therapeutics Corp.|
Txns:
| Bought 30,000 shares
@ $0.431, valued at
$12.9k
|
|
| 06/06/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/17/2023 |
DEL AM
| Form DEL AM - Delaying amendment: |
| 05/12/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/20/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/04/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/14/2023 |
3
| PD Joint Holdings, LLC Series 2016-A (10% Owner) has filed a Form 3 on Pasithea Therapeutics Corp. |
| 01/24/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 01/13/2023 |
SC 13G/A
| Khire Uday reports a 4.6% stake in Pasithea Therapeutics Corp. |
| 01/10/2023 |
SC 13D/A
| Camac Fund, LP reports a 0% stake in Pasithea Therapeutics Corp. |
| 12/14/2022 |
8-K
| Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Fi...|
Docs:
|
"SETTLEMENT AND COOPERATION AGREEMENT This Settlement and Cooperation Agreement is made and entered into as of December 9, 2022, by and among Pasithea Therapeutics Corp. , on the one hand, and Concord IP2 Ltd., Elderhill Corporation, Leonite Capital LLC, Leonite Fund I, LP, Camac Partners, LLC, Camac Capital, LLC, Camac Fund, LP, David Delaney, Avi Geller, and Eric Shahinian , on the other hand . RECITALS",
"Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group MIAMI BEACH, Fla., Dec. 12, 2022 -- Pasithea Therapeutics Corp. , a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system disorders, today announced that it has reached a comprehensive Settlement and Cooperation Agreement with Concord IP2 Ltd., Elderhill Corporation, Leonite Capital LLC, Leonite Fund I, LP, Camac Partners, LLC, Camac Capital, LLC, Camac Fund, LP, David Delaney, Avi Geller, and Eric Shahinian resolving all outstanding issues between the parties. Pursuant to the Agreement, the Camac Group has agreed to a three-year standstill provision and the parties have agreed to dismiss with prejudice the pending Delaware litigatio..." |
|
| 12/07/2022 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 11/30/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 11/30/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 11/29/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 11/28/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 11/28/2022 |
4
| STEINMAN LAWRENCE (Director) has filed a Form 4 on Pasithea Therapeutics Corp.|
Txns:
| Granted 5,000 shares
@ $0.98, valued at
$4.9k
|
|
| 11/28/2022 |
4
| Marques Tiago (CEO) has filed a Form 4 on Pasithea Therapeutics Corp.|
Txns:
| Granted 5,000 shares
@ $1, valued at
$5k
Granted 1,000 shares
@ $1.03, valued at
$1k
Granted 1,206 shares
@ $1.02, valued at
$1.2k
Granted 2,000 shares
@ $1.03, valued at
$2.1k
|
|
| 11/22/2022 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 11/22/2022 |
4
| STEINMAN LAWRENCE (Director) has filed a Form 4 on Pasithea Therapeutics Corp.|
Txns:
| Granted 5,000 shares
@ $0.99, valued at
$5k
|
|
| 11/17/2022 |
DEFC14A
| Form DEFC14A - Definitive proxy statement, contested solicitations: |
|
|
|